AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03083418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDP
Description: Turn on the device, and clean the skin where the patch will be located according to the screen tip. Paste the two groups of small electrodes to the inferior 1/3 of the outer edge of bilateral sternocleidomastoid, and the large electrodes are pasted to the corresponding 2nd intercostal skin surface of pectoralis major at midclavicular line.Adjusting the stimulus intensity according to the daily maximum tolerance (patients with no pain and tension).30 minutes continuous stimulation each time, twice a day, a total of one weeks of treatment .
Study NCT00570271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo with BP dec (written form)
Description: Placebo administration with a blood pressure decrease suggestion. Information provided to subjects in written form.
Study NCT00570271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo with BP dec (doctor)
Description: Placebo administration with a blood pressure decrease suggestion. Information provided to subjects by doctor.
Study NCT00570271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo with BP inc (written)
Description: Placebo administration with a blood pressure increase suggestion. Information provided to subjects in written form.
Study NCT03775928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib 425mg qd po
Study NCT03775928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: capecitabine 1000mg/m2 bid d1-d14
Study NCT03775928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: capecitabine 1000mg/m2 bid d1-d14
Study NCT03030859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Undergo usual care only
Study NCT03030859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care plus LEF-SCP
Description: Undergo Motivational Interviewing sessions and LEF Self-Care Training sessions, as well as review LEF self-care educational manual and videos
Study NCT03030859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care plus LEF-SCP plus Follow-up
Description: Undergo Motivational Interviewing sessions and LEF Self-Care Training sessions, and review LEF self-care educational manual and videos, as well as meet with the study lymphedema therapist
Study NCT04276415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-6157a
Description: Administered as a single agent intravenously (IV) every 3 weeks
Study NCT00570271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo with BP inc (doctor)
Description: Placebo administration with a blood pressure increase suggestion. Information provided to subjects by doctor.
Study NCT00570271 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Placebo info given (written)
Description: Subject informed about receiving placebo. Information provided to subjects in written form.
Study NCT00570271 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Placebo info given (doc)
Description: Subject informed about receiving placebo. Information provided to subjects by doctor.
Study NCT02040766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate BAI
Description: Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a breath-actuated inhaler (BAI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.
Study NCT02040766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo BAI
Description: Placebo was delivered by a single inhalation using a breath-actuated inhaler (BAI) twice each day.
Study NCT02040766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BAI
Description: Placebo was delivered by a single inhalation using a breath-actuated inhaler (BAI) twice each day.
Study NCT02040766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol 90 mcg
Description: Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
Study NCT02040766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol/salbutamol 90 mcg
Description: Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
Study NCT02040766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albuterol/salbutamol 90 mcg
Description: Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
Study NCT02040766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone dipropionate MDI
Description: Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a metered-dose inhaler (MDI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.
Study NCT02040766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo MDI
Description: Placebo was delivered by a single inhalation using a metered-dose inhaler (MDI) twice each day.
Study NCT02040766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Placebo was delivered by a single inhalation using a metered-dose inhaler (MDI) twice each day.
Study NCT04281680 — intervention group
Intervention type: DRUG
Intervention: Pasireotide 0.9 MG/ML
Description: 900-ug pasireotide administered subcutaneously twice daily for a week or until discharged from the hospital
Study NCT04725149 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 500 ml base solution
Description: Color, taste, aroma, and calorie matched water base
Study NCT04725149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 500 ml containing 30 ml tart cherry concentrate diluted with water and base solution
Description: Montmorency cherry concentrate
Study NCT04725149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 500 ml containing 60 ml tart cherry concentrate diluted with water only
Description: Montmorency cherry concentrate
Study NCT02704351 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Sugammadex to reverse neuromuscular blockade
Study NCT00764309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Tablets, Oral, 100 mg, once daily, 6 months
Study NCT04578743 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy: ClearPlay(TM)
Description: ClearPlayTM; a novel therapeutic intervention, downloadable to an Apple i-touch or i-phone device, that provides a telemetry-based graded exercise program that enables remote monitoring of symptoms.
Study NCT03378700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Hope Intervention
Description: The present Brief Hope Intervention (BHI) is a four-weeks individual intervention, consisting of four sessions: two face-to-face sessions (1-hour) and two telephone follow up sessions (30 minutes) in between.~The facilitator will guide participants to imagine how they navigate themselves to circumvent possible obstacles and accomplished their set goals and experience positive emotions.~A booklet will be given to the participants for reviewing their planned goals, recording achieved targets and successful experiences.
Study NCT03378700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-dialysis Education Group
Description: Pre-dialysis educational class and standard care such as clinic follow up and normal hospital care will be provided. This session is led by clinicians with renal nursing training. The educational class aims at providing information on the treatment modalities for patients with ESRD, signs and symptoms of their illness and the basic advice on the importance of adherence to healthy lifestyle, nutrition and medications. Logistic call and social communication will be offered and initiated by trained nurses in the second week and the third week
Study NCT02419352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Study NCT02419352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine/atropine
Study NCT00765700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Ketoprofen 10% Cream
Description: Topical Administration
Study NCT00765700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Placebo Cream
Description: Topical Administration
Study NCT00584766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Description: Cyclophosphamide 500 mg/m2 IV day 1; Doxorubicin 30 mg/m2 IV Day 1; Methotrexate 300 mg/m2 IV Day 8;5-FU 500 mg/m2 IV day 8; leucovorin 20 mg po q 6 h x 6 doses, day 9- cycles repeated q 21 days
Study NCT02473809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Once daily
Study NCT02473809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study NCT02936375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Prednisone, methylprednisolone or prednisonlone, once a day, orally administrated. Steroids should be 1mg/kg·d in the beginning four weeks, then tapered 5-10mg/d every two weeks till 30mg/d, then tapered 2.5-5mg/d every two weeks. After 24 weeks of follow-up, a patient should receive steroids no more than 10mg/d. Patients may receive temporal high dose of steroids (1mg/kg·d) because of symptoms outside of kidney, for no more than two weeks. All the dosage of steroids above is calculated by prednisone.
Study NCT01106131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5mg
Description: CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with metformin.
Study NCT01106131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 15mg
Description: Pioglitazone 15mg, orally, 1 tablet or 2 tablet(if confirmed case) once a day for 24weeks with metformin.
Study NCT01118013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Study NCT01118013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor lymphocytes
Study NCT01118013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT01118013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Study NCT01118013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Study NCT01118013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT01118013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00661089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A - OnabotulinumtoxinA
Description: 100-200 units injected into the pectoralis major. The teres major may also be injected if tone is noted in shoulder extensors.
Study NCT01118013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Study NCT00661089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Saline)
Description: Equivalent volume of saline without study drug injected into the pectoralis major. Teres major was also injected if tone noted in the shoulder extensors.
Study NCT01118013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Study NCT01118013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reduced-intensity transplant conditioning procedure
Study NCT01305564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Denali inferior vena cava filter
Description: The Denali inferior vena cava filter is a mechanical filtration device consisting of two levels of filtration (upper arms, lower legs), a retrieval hook to allow for retrieval using a standard snare, cranial and caudal anchors, and penetration limiters. The Denali filter is made from a laser cut nitinol tube.
Study NCT01088971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Duolac7S
Description: 1 capsule two times everyday for 6 weeks
Study NCT01088971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: starch
Description: 1capsule two times everyday for 6 weeks
Study NCT01187732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Washing without water
Description: The experimental intervention is 'washing without water' and consists of disposable washing cloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion.
Study NCT01187732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Washing without water
Description: The experimental intervention is 'washing without water' and consists of disposable washing cloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion.
Study NCT00274742 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab (MT103)
Description: Doses from 0.5 to 120 µg/m\^2/24hours by continuous intravenous infusion
Study NCT02786992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Study NCT01118013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Study NCT01118013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT01142115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent catheter CP063CC
Description: intermittent catheterisation
Study NCT01142115 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent catheter CP063CC
Description: intermittent catheterisation
Study NCT01142115 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SpeediCath
Description: intermittent catheterisation
Study NCT02773004 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EPClin genomic test
Study NCT00599443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal cell-derived influenza vaccine
Description: 0.5 mL im, single dose
Study NCT00599443 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 0.5 mL im, single dose
Study NCT03321877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Change to dose of patient's regular medication
Description: Dose reduction of the drug each patient was already taking
Study NCT04445987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ-154
Description: ARQ-154 foam 0.3% applied once daily for 52 weeks
Study NCT02091206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P 5 mg/kg/day Dose
Description: GWP42003-P was an oral solution containing 25 mg/milliliter (mL) cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
Study NCT02091206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Study NCT02091206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P 10 mg/kg/day Dose
Description: GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
Study NCT02091206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P 20 mg/kg/day Dose
Description: GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
Study NCT01141153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid + clopidogrel + acenocoumarol
Description: Acetylsalicylic Acid 100 mg daily + Clopidogrel 75 mg daily + Acenocoumarol dosage with INR monitoring~Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent
Study NCT01141153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic Acid + clopidogrel
Description: Salicylic Acid, 300 mg daily + Clopidogrel 75 mg daily~Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent.
Study NCT02341443 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implants
Description: Experimental arm: Rigid~Surgical treatment using arch bars and according to the following fixation:~Rigid fixation on one side (most anterior fracture) and non-rigid fixation on the other (most posterior fracture).~Active comparator: Non-rigid~Surgical treatment using arch bars and according to the following fixation:~Non-rigid fixation on both fracture sides.~Whereas non-rigid fixation is defined as a single miniplate of ≤1.00 mm thickness, and rigid fixation is defined as a single plate of ≥1.25 mm thickness, a combination of 2 plates or a 3D geometric plate.
Study NCT02341443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implants
Description: Experimental arm: Rigid~Surgical treatment using arch bars and according to the following fixation:~Rigid fixation on one side (most anterior fracture) and non-rigid fixation on the other (most posterior fracture).~Active comparator: Non-rigid~Surgical treatment using arch bars and according to the following fixation:~Non-rigid fixation on both fracture sides.~Whereas non-rigid fixation is defined as a single miniplate of ≤1.00 mm thickness, and rigid fixation is defined as a single plate of ≥1.25 mm thickness, a combination of 2 plates or a 3D geometric plate.
Study NCT00329810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Tablets, oral, 15 mg, once daily, 12 weeks.
Study NCT01869023 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Combination of Gemcitabine 250 mg/m2 in six hour infusion with cisplatin 35 mg/m2 administered day 1 and 8, for six cycles.
Study NCT01869023 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Cisplatin 35 mg/m2SC applied on day 1 of 3 weeks cycles
Study NCT02193126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trauma Affect Regulation: Guide for Education and Therapy (TARGET)
Description: The intervention is called the Trauma Affect Regulation: Guide for Education and Therapy (TARGET). TARGET is a manualized, psycho-educational intervention delivered in 10 - 12 sessions. TARGET is designed to address complex trauma and difficulties with emotional regulation and relational engagement that occur across a wide range of trauma-related difficulties, including trauma-related and behavioral symptoms. The full TARGET model consists of learning 7 essential core skills. These skills are called the FREEDOM steps: Focus, Recognize triggers, Emotion self-check, Evaluate thoughts, Define goals, Options, and Make a contribution.
Study NCT01546675 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skeletal Stabilization
Description: Upper Limb Prosthetic Socket hypothesized to increase skeletal stabilization
Study NCT01546675 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skeletal Stabilization
Description: Upper Limb Prosthetic Socket hypothesized to increase skeletal stabilization
Study NCT02786992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study NCT02786992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Study NCT02786992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT05296707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The MIP/MEP value of the group that will receive inspiratory muscle training was determined and Threshold IMT training was given with 30%.~In the training, the subjects were asked to sit in a relaxed position with their upper chest and shoulders relaxed.~After the nose clip was attached, the children were asked to inhale and exhale by tightly closing the mouthpiece of the instrument with their lips.~A 30-minute training session was carried out for 6 weeks, with 10-15 repetitive breathing apparatus and 5-10 seconds rest breaks every day.
Study NCT05296707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Used routine medicine
Description: After the first evaluation was made, a second evaluation was made after 6 weeks of follow-up.
Study NCT05296707 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Used routine medicine
Description: After the first evaluation was made, a second evaluation was made after 6 weeks of follow-up.
Study NCT05296707 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: A healthy child compatible with the age and sex of the patient group was evaluated once.
Study NCT04098562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LL37
Description: cream
Study NCT04098562 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Wound Care
Description: Standard wound debridement